Our NGS Oncology Panel Service provides validated and optimized NGS panels that include cancer oncogenes and tumor suppressors. This service features PGM AmpliSeq, and MiSeq TruSeq cancer panels, both powered by our proprietary NGS workflow from sample preparation to data reporting. Our NGS Oncology Panel Service is optimized to detect and to report most critical mutations across the targeted genes, beyond the typical reporting of hot spot mutations. These oncology panels are now launched through our centralized CLIA/CAP testing laboratories and offer turnaround times of 10 days or less:
Hotspot Cancer Panel (HCP 50) - HCP 50 utilizes Ampliseq™ chemistry to amplify hotpsot regions from 50 of the most clinically relevant cancer genes from FFPE tissue. A proprietary library workflow enables preparation of Ion PGM™ and Illumina© sequencing-ready libraries in parallel with as little as 10 ng of genomic DNA. The benefit of this workflow is that it overcomes the challenges associated with single base indel errors from homopolymer regions that can occur. In addition, MolecularMD has developed and validated a three-tiered data analysis pipeline for Ion PGM and Illumina MiSeq sequencing. For complicated long indels, a local realignment can be used to recover the soft clipped regions and enhance long indel detection.
Liquid Biopsy Hotspot Cancer Panel (LBx HCP 50) - LBx HCP 50 utilizes AmpliSeq chemistry to amplify hotspot regions from 50 of the most clinically relevant cancer genes. Obtain accurate and sensitive results with plasma samples as small as 5 ng of DNA. The average amplicon length of 154 bp is short enough to detect mutations from ctDNA in plasma. It has been cited that ctDNA characteristically has short 175-1000 base pair fragments, enabling acceptable performance in plasma as a sample type. MolecularMD has performed validation of LBx HCP 50 using plasma and matched tumor samples from Melanoma, Breast and Colorectal cancers. An enhanced library workflow and proprietary bioinformatics tools aid in delivering high performance results.
Comprehensive Cancer Panel (CCP 143) - CCP 143 is a validated version of ThermoFisher's Oncomine® Comprehensive Assay that sequences 143 clinically relevant cancer genes, including both oncogenes and oncosuppressors, gene copy number and gene fusion events. The CCP 143 assay utilizes the Ion Torrent™ PGM platform and employs AmpliSeq™ library preparation chemistry. The assay also incorporates data annotation by the Oncomine® Knowledgebase, one of the world's largest comprehensive expert-curated cancer databases. With only 20 ng DNA and 10 ng RNA from an FFPE sample, CCP 143 is designed to simultaneously detect and report out hotspot mutations, CNVs, gene fusions and indels in a single sequencing run.
Liquid Biopsy Using the Ion AmpliSeq™ v2 Cancer Panel - 2015 AACR Poster
Oncomine Cancer Research Panel: Simultaneous Detection of Clinically Relevant Hotspot Mutations, CNVs and Gene Fusions in Solid Tumors - 2015 AACR Poster